Payment overview · 2025
General Payments
$111.87
6 reported records · 4 companies
Healthcare provider profile · identity verified
Miranda Nash, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · STEPHENVILLE, TX · NPI 1235398140
Verified facts
What the public records show
CMS Open Payments records show Miranda Nash, M.D. received $111.87 in general payments during 2025 across 6 reported records.
Amgen Inc. accounted for 45.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 5 associated products.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Prolia by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 157 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $50.48 | 45.1% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $25.22 | 22.5% | 1 | 2025 |
| INOGEN, INC. | Unresolved — no canonical attribution shown | $22.15 | 19.8% | 1 | 2025 |
| ABIOMED | Unresolved — no canonical attribution shown | $14.02 | 12.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $111.87 | 6 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $50.48 | 3 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $25.22 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $25.22 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $25.22 | 1 | 2025 |
Source payment records
|
|||||
| INOGEN ONE G5 OXYGEN CONCENTRATOR - BLUETOOTH Normalized: inogen one g5 oxygen concentrator bluetooth |
Device | INOGEN, INC. | $22.15 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
40 | 25 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
157 | 37 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
17 | 17 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 904 | 213 |
| Gabapentin | Gabapentin | 612 | 180 |
| Losartan Potassium | Losartan Potassium | 568 | 154 |
| Atorvastatin Calcium | Atorvastatin Calcium | 523 | 141 |
| Lisinopril | Lisinopril | 444 | 120 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 429 | 136 |
| Metformin Hcl | Metformin Hcl | 407 | 106 |
| Omeprazole | Omeprazole | 398 | 111 |
| Amlodipine Besylate | Amlodipine Besylate | 388 | 120 |
| Simvastatin | Simvastatin | 365 | 108 |
| Pantoprazole Sodium | Pantoprazole Sodium | 344 | 106 |
| Mounjaro | Tirzepatide | 306 | 45 |
| Trazodone Hcl | Trazodone Hcl | 275 | 78 |
| Metoprolol Succinate | Metoprolol Succinate | 270 | 77 |
| Montelukast Sodium | Montelukast Sodium | 242 | 58 |
| Hydrochlorothiazide | Hydrochlorothiazide | 240 | 71 |
| Duloxetine Hcl | Duloxetine Hcl | 239 | 58 |
| Sertraline Hcl | Sertraline Hcl | 236 | 62 |
| Pravastatin Sodium | Pravastatin Sodium | 222 | 50 |
| Metoprolol Tartrate | Metoprolol Tartrate | 210 | 50 |
| Alendronate Sodium | Alendronate Sodium | 180 | 55 |
| Furosemide | Furosemide | 165 | 50 |
| Eliquis | Apixaban | 157 | 37 |
| Fluoxetine Hcl | Fluoxetine Hcl | 155 | 44 |
| Diclofenac Sodium | Diclofenac Sodium | 148 | 69 |
| Tamsulosin Hcl | Tamsulosin Hcl | 147 | 37 |
| Escitalopram Oxalate | Escitalopram Oxalate | 140 | 39 |
| Potassium Chloride | Potassium Chloride | 137 | 37 |
| Ozempic | Semaglutide | 136 | 28 |
| Donepezil Hcl | Donepezil Hcl | 132 | 29 |
| Citalopram Hbr | Citalopram Hydrobromide | 131 | 29 |
| Methylprednisolone | Methylprednisolone | 126 | 105 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 122 | 31 |
| Hydralazine Hcl | Hydralazine Hcl | 119 | 33 |
| Carvedilol | Carvedilol | 117 | 33 |
| Finasteride | Finasteride | 114 | 24 |
| Fluticasone Propionate | Fluticasone Propionate | 110 | 33 |
| Glipizide Er | Glipizide | 109 | 30 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 108 | 31 |
| Tramadol Hcl | Tramadol Hcl | 107 | 25 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 96 | 48 |
| Allopurinol | Allopurinol | 96 | 26 |
| Bupropion Xl | Bupropion Hcl | 93 | 20 |
| Tizanidine Hcl | Tizanidine Hcl | 91 | 49 |
| Alprazolam | Alprazolam | 84 | 22 |
| Meloxicam | Meloxicam | 84 | 30 |
| Prednisone | Prednisone | 84 | 44 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 80 | 20 |
| Nystatin | Nystatin | 79 | 31 |
| Doxycycline Hyclate | Doxycycline Hyclate | 76 | 59 |
| Pregabalin | Pregabalin | 75 | 18 |
| Zolpidem Tartrate | Zolpidem Tartrate | 74 | 17 |
| Amitriptyline Hcl | Amitriptyline Hcl | 73 | 32 |
| Metformin Hcl Er | Metformin Hcl | 72 | 20 |
| Januvia | Sitagliptin Phosphate | 68 | 11 |
| Ropinirole Hcl | Ropinirole Hcl | 68 | 17 |
| Synthroid | Levothyroxine Sodium | 68 | 19 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 67 | 59 |
| Buspirone Hcl | Buspirone Hcl | 66 | 12 |
| Azithromycin | Azithromycin | 65 | 59 |
| Myrbetriq | Mirabegron | 64 | 17 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 64 | 15 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 63 | 13 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 63 | 17 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 58 | 15 |
| Quetiapine Fumarate | Quetiapine Fumarate | 58 | 16 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 56 | 17 |
| Glipizide | Glipizide | 53 | 17 |
| Clopidogrel | Clopidogrel Bisulfate | 51 | 14 |
| Memantine Hcl | Memantine Hcl | 51 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 50 | 16 |
| Gemfibrozil | Gemfibrozil | 48 | 12 |
| Ondansetron Odt | Ondansetron | 47 | 30 |
| Celecoxib | Celecoxib | 46 | 15 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 46 | 24 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 45 | 31 |
| Ezetimibe | Ezetimibe | 45 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 44 | 14 |
| Glimepiride | Glimepiride | 43 | 14 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 42 | 34 |
| Famotidine | Famotidine | 42 | 15 |
| Acyclovir | Acyclovir | 41 | 12 |
| Amiodarone Hcl | Amiodarone Hcl | 41 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 40 | suppressed |
| Prolia | Denosumab | 40 | 25 |
| Warfarin Sodium | Warfarin Sodium | 38 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 37 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 34 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 34 | 30 |
| Divalproex Sodium | Divalproex Sodium | 32 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 32 | suppressed |
| Primidone | Primidone | 31 | 11 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 30 | suppressed |
| Atenolol | Atenolol | 29 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 29 | suppressed |
| Lovastatin | Lovastatin | 29 | suppressed |
| Amoxicillin | Amoxicillin | 28 | 25 |
| Xarelto | Rivaroxaban | 28 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 27 | suppressed |
| Cephalexin | Cephalexin | 25 | 19 |
| Estradiol | Estradiol | 25 | 11 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 25 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 24 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 24 | suppressed |
| Lorazepam | Lorazepam | 24 | suppressed |
| Nifedipine Er | Nifedipine | 24 | suppressed |
| Spironolactone | Spironolactone | 24 | suppressed |
| Topiramate | Topiramate | 24 | suppressed |
| Fenofibrate | Fenofibrate | 23 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 22 | suppressed |
| Jardiance | Empagliflozin | 22 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 22 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 21 | suppressed |
| Clonazepam | Clonazepam | 21 | suppressed |
| Lamotrigine | Lamotrigine | 21 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 21 | 15 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 20 | suppressed |
| Mirabegron Er | Mirabegron | 20 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 20 | suppressed |
| Temazepam | Temazepam | 20 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 20 | suppressed |
| Valsartan | Valsartan | 20 | suppressed |
| Atomoxetine Hcl | Atomoxetine Hcl | 18 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 18 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 18 | suppressed |
| Levetiracetam | Levetiracetam | 18 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 18 | suppressed |
| Trulicity | Dulaglutide | 18 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 18 | suppressed |
| Aripiprazole | Aripiprazole | 17 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 17 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 17 | 17 |
| Diltiazem 24hr Er | Diltiazem Hcl | 16 | suppressed |
| Irbesartan | Irbesartan | 16 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 15 | suppressed |
| Fluconazole | Fluconazole | 15 | 13 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 15 | 12 |
| Mometasone Furoate | Mometasone Furoate | 15 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 15 | suppressed |
| Telmisartan | Telmisartan | 15 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 15 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 15 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Methotrexate | Methotrexate Sodium | 14 | suppressed |
| Naproxen | Naproxen | 14 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 14 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 14 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 13 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 13 | suppressed |
| Np Thyroid | Thyroid,pork | 13 | suppressed |
| Ramipril | Ramipril | 13 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 13 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 12 | suppressed |
| Digoxin | Digoxin | 12 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 12 | suppressed |
| Levalbuterol Tartrate Hfa | Levalbuterol Tartrate | 12 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 12 | 12 |
| Sucralfate | Sucralfate | 12 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 11 | suppressed |
| Ertapenem | Ertapenem Sodium | 11 | suppressed |
| Mono-Linyah | Norgestimate-Ethinyl Estradiol | 11 | suppressed |
| Nitroglycerin | Nitroglycerin | 11 | suppressed |
| Olanzapine | Olanzapine | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $111.87 · 6 records | Amgen Inc. | ABRYSVO, COMIRNATY, INOGEN ONE G5 OXYGEN CONCENTRATOR - BLUETOOTH, KRYSTEXXA, PREVNAR 20 | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with Amgen Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error